Literature DB >> 15538132

Effects of naltrexone on the subjective response to amphetamine in healthy volunteers.

Nitya Jayaram-Lindström1, Peter Wennberg, Yasmin L Hurd, Johan Franck.   

Abstract

While dopaminergic mechanisms in amphetamine-taking behavior have been extensively studied, the contribution of the endogenous opioid system is less clear. We assessed the effects of an opioid antagonist, naltrexone (50 mg), on the subjective response to an oral dose of dexamphetamine (30 mg) in 12 healthy volunteers in a double-blind, placebo-controlled design. Volunteers received a total of 4 combinations of the study preparation (placebo-naltrexone, placebo-amphetamine) over 4 occasions with 1-week intervals. The primary objective of the study was to evaluate the effect of pretreatment with naltrexone on the subjective response to amphetamine. This was measured using a Visual Analog Scale, assessing the subjective effects over 7 hours. The secondary objective was to measure the effects of naltrexone on behavioral and physiologic responses to amphetamine. This was measured by blood pressure, heart rate, skin conductance, and speed of reading at the end of each session. Amphetamine produced significant effects on subjective arousal when compared to placebo after 1 hour (P < 0.001) and continued to be evident until 7 hours. Pretreatment with naltrexone significantly attenuated the subjective effects of amphetamine (P < 0.05), and this effect was time-dependent with a reduction from the 3-hour time point. Naltrexone did not influence the behavioral and physiologic effects of amphetamine in this sample. The results provide preliminary evidence that naltrexone may reduce the reinforcing effects of amphetamine via modulation of the opioid system. The potential of naltrexone as an adjunct pharmaceutical for the treatment of amphetamine dependence is promising and needs to be investigated further.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538132     DOI: 10.1097/01.jcp.0000144893.29987.e5

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  31 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  The neuromodulator of exploration: A unifying theory of the role of dopamine in personality.

Authors:  Colin G Deyoung
Journal:  Front Hum Neurosci       Date:  2013-11-14       Impact factor: 3.169

3.  Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.

Authors:  Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki
Journal:  Addiction       Date:  2017-08-29       Impact factor: 6.526

Review 4.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

Review 5.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

Review 6.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

7.  Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.

Authors:  Reshmi Pal; John E Mendelson; Keith Flower; Kathleen Garrison; Garret Yount; Jeremy R Coyle; Gantt P Galloway
Journal:  J Addict Med       Date:  2015 Mar-Apr       Impact factor: 3.702

8.  Riluzole and D-amphetamine interactions in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Thomas Kosten
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-05-18       Impact factor: 5.067

9.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 10.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.